



Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results

March 6, 2024

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- [Belite Bio, Inc.](#) (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, March 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the fourth quarter and full year ended December 31, 2023.

Webcast Information

Date: Tuesday, March 12, 2024

Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)

Webcast Link: <https://wsw.com/webcast/cc/blte2/1419894>

Webcast Link Instructions

You can join the live webcast by visiting the link above or the "Presentations & Events" section of the Company's Investor Relations website at <https://investors.belitebio.com/presentations-events/events>. A replay will be available for approximately 90 days after the event.

About Belite Bio

Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinklarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on [Twitter](#), [Instagram](#), [LinkedIn](#), [Facebook](#), or visit us at www.belitebio.com.

Media and Investor Relations Contact:

Jennifer Wu

ir@belitebio.com

Julie Fallon

belite@argotpartners.com